Market capitalization | SEK23.27b |
Enterprise Value | SEK29.26b |
P/E (TTM) P/E ratio | 23.22 |
EV/FCF (TTM) EV/FCF | 14.18 |
EV/Sales (TTM) EV/Sales | 1.65 |
P/S ratio (TTM) P/S ratio | 1.31 |
P/B ratio (TTM) P/B ratio | 2.23 |
Dividend yield | 3.94% |
Last dividend (FY23) | SEK2.40 |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
17 Analysts have issued a Elekta AB forecast:
17 Analysts have issued a Elekta AB forecast:
Oct '24 |
+/-
%
|
||
Revenue | 17,726 17,726 |
2%
2%
|
|
Gross Profit | 6,421 6,421 |
8%
8%
|
|
EBITDA | 2,658 2,658 |
15%
15%
|
EBIT (Operating Income) EBIT | 2,027 2,027 |
20%
20%
|
Net Profit | 1,003 1,003 |
25%
25%
|
In millions SEK.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Elekta AB is a medical technology company. It engages in the provision of clinical solutions for the treatment of cancers and brain disorders. The firm's products and solutions include radiotherapy, stereotactic radiosurgery, oncology informatics, brachytheraphy, neurosurgery, and particle therapy. Elekta operates through the following geographical segments: North and South America; Europe, Middle East and Africa; and Asia Pacific. The company was founded by Lars Leksell and Laurent Leksell in 1972 and is headquartered in Stockholm, Sweden.
Head office | Sweden |
CEO | Gustaf Salford |
Employees | 4,641 |
Founded | 1972 |
Website | www.elekta.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.